Vall d'Hebron leads an international phase III clinical trial demonstrating the efficacy of atogepant, an oral drug for the prevention of chronic migraine

by Vall d’Hebron

Atogepant is the first oral drug that can be useful for patients with chronic migraine, which makes it easier to access, provides flexibility in drug administration and is easier to store, since injec...

Read more
Subscribe to Directory
Write an Article

Recent News

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Un ensayo de microscopía dinámica del ...

by CSIC - Centro Superior de Investigaciones Científicas

La revista ‘Nature Protocols’ selecciona esta técnica como “pro...

Photos Stream